GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (FRA:9Y4) » Definitions » Cash Receipts from Fees and Commissions

Ryvu Therapeutics (FRA:9Y4) Cash Receipts from Fees and Commissions


View and export this data going back to 2021. Start your Free Trial

What is Ryvu Therapeutics Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


Ryvu Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (FRA:9Y4) » Definitions » Cash Receipts from Fees and Commissions
Traded in Other Exchanges
Address
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.